% | $
Quotes you view appear here for quick access.

Shire plc Message Board

  • stock_driver stock_driver Apr 25, 2007 12:38 PM Flag

    Citigroup Upgrades $83 before earnings

    Citigroup Upgrades Shire Pharmaceuticals (SHPGY) to Buy
    04-24-2007 09:51:43 AM
    More Upgrades

    S&P Equity Research Upgrades Advanced Medical Optics (EYE) to Hold
    S&P Equity Research Upgrades Boston Properties (BXP) to Hold
    KeyBanc upgrades Albemarle Corporation (ALB) to Buy
    Friedman Billings upgrades Verint Systems (VRNT) to Outperform
    Raymond James upgrades O'Reilly Auto (ORLY) to Strong Buy

    Citigroup upgrades Shire Pharmaceuticals (Nasdaq: SHPGY) from Hold to Buy. Price target increased from $71 to $83.

    Citigroup analyst says, "Q1 results poised to beat consensus expectations - From our analysis of prescription and pricing trends we believe Q1 results (Wednesday 25 April) will beat consensus expectations and give the market confidence Shire is executing on its multiple product launches. In particular, we expect Adderall XR and Elaprase to comfortably exceed consensus at $233m and $24m, respectively (CIR $240m and $30m). We upgrade our 2007 and 2008 'cash' EPS forecasts by 5% and 3%, respectively."

    SortNewest  |  Oldest  |  Most Replied Expand all replies